AstraZeneca: Lynparza Trial Has Met Primary Endpoint
05 June 2017 - 4:47PM
Dow Jones News
LONDON--AstraZeneca PLC (AZN.LN) said Monday that the phase 3
trial of treatment drug Lynparza has met its primary endpoint.
The pharmaceutical company said the trial showed a
statistically-significant and clinically-meaningful improvement in
progression-free survival for patients treated with Lynparza
tablets, compared to chemotherapy.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
June 05, 2017 02:32 ET (06:32 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025
